Engineering olivocochlear inhibition to reduce acoustic trauma.

"Declaration of interests The authors declare no competing or other financial interests."

"We thank F. Chakir for outstanding technical support, J.M. McIntosh for Cy3-RgIA-5727 Conus peptide, B.J. May for the ABR threshold app, and A. Goldring for developing the viral injection protocol in our laboratory. Funding was provided by the 10.13039/100000055National Institute on Deafness and Other Communication Disorders, grants R01 DC001508 (P.A.F., A.B.E.) and R01DC017620 (A.L.), and the David M. Rubenstein Fund for Hearing Research and Professorship (P.A.F.). Author contributionsExperiments were designed by Y.Z., H.H., P.F.V.Y., M.B.W., A.B.E., and P.A.F. Methodology was perfected by Y.Z., H.H., P.F.V.Y., M.B.W., W.C., A.B.E., and A.L. Experimental work and visualization were conducted by Y.Z., H.H., P.F.V.Y., M.B.W., and P.A.F. Funding was acquired by P.A.F., A.B.E., and A.L. The project was administered by P.A.F. and H.H. Supervision was conducted by P.A.F. and A.L. P.A.F. wrote the original draft. Manuscript review and editing were completed by Y.Z., H.H., P.F.V.Y., M.B.W., A.B.E., W.C., A.L., and P.A.F."